Jorge Chaves is an Oncology physician affiliated with Northwest Medical Specialties. OpenAlex indexes 54 publications with 3,049 citations (h-index 19); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1624 South I Street
Suite 102
Tacoma, WA 984055093
Telephone
253-383-3366Registry record last updated 1 Nov 2017.
Clinical trials
- BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Sponsor: Boryung Pharmaceutical Co., Ltd
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
48 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20258 payments
- Janssen Biotech, Inc.Program year20255 payments
- Incyte CorporationProgram year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
53.5%Other antiemetics47.9%Fosaprepitant100%Part B, office-administered≥24 patientsSerotonin-3 Receptor Antagonist5%Palonosetron hcl76%Ondansetron hydrochloride21%Ondansetron Odt2%Part D + Part B≥27 patients+ 4 more classes in this area
Cancer & immunology
23.6%PD-1 inhibitor20.1%Pembrolizumab100%Part B, office-administered≥11 patientsNucleoside Metabolic Inhibitor2.2%Fluorouracil100%Part B, office-administered≥14 patients+ 7 more classes in this area
Musculoskeletal
7%RANK Ligand Inhibitor6.3%Denosumab100%Part B, office-administered≥13 patientsBisphosphonate0.7%Zoledronic acid100%Part B, office-administered≥25 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
William Hirota, MD
Northwest Medical Specialties
Francis Senecal, MD
Northwest Medical Specialties
Andrea Veatch, MD
Northwest Medical Specialties
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”